With China's new healthcare reform aiming
to provide an affordable health care system to its population, pharmacoeconomics is an
area receiving more attention every year. In August 2009, China announced the New National
Essential Medicine List, which utilizes pharmacoeconomics as an important evaluation
factor in the selection of listed drugs, demonstrating its wide recognition among
the Chinese government. Capped healthcare budgets and rising drug costs have led to a
high level of interest in the use of economic analysis for drug evaluation in China.
Pharmacoeconomics is crucial in a world with an ageing population and a strained healthcare
budget. Pharmaceutical and biotech companies must be able to measure and
prove the value of their products in more sophisticated ways and be accountable for more
factors. Therefore, advancements in pharmacoeconomics and greater understanding of consequences in the broader context of healthcare economics are essential.
Pharmacoeconomics and Outcomes Research Congress 2010 is a 2-day event that brings together drug developers, government officers, and solution providers to discuss China's pharmacoeconomics development. Attendees will learn about recent breakthroughs and regulations, such as the drug pricing, life-cycle management and the role of pharmacoeconomics in China's new medical reform. This event will also provide insights into healthcare costs and results of your decision
making.
|
